Nick Glover

Director/Board Member at LITE STRATEGY, INC.

Net worth: - $ as of 30/09/2026

57 year

63 connections

Health Technology

Consumer Services

Finance

Profile

Dr. Nicholas R.
Glover is an Independent Non-Executive Director at Lite Strategy, Inc., a Chief Executive Officer at MycRX and a Chief Executive Officer at MycRx Holdings, Inc. He is on the Board of Directors at Lite Strategy, Inc. and Pattern Pharma, Inc. Dr. Glover was previously employed as a President, Chief Executive Officer & Director by Sierra Oncology, Inc., a President, Chief Executive Officer & Director by YM BioSciences, Inc., a President, Chief Executive Officer & Director by Viventia Biotech, Inc., an Investment Manager by Lumira Capital Investment Management, Inc., a Chief Executive Officer by ProNAi Therapeutics, Inc., and an Investment Analyst by University Medical Discoveries, Inc. He received his undergraduate degree from the University of East Anglia, a graduate degree from the University of British Columbia and a doctorate degree from Simon Fraser University.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
LITE STRATEGY INC -.--%	22/09/2026	0 ( -.--% )	- $	30/09/2026

Nick Glover active positions

Companies	Position	Start
LITE STRATEGY, INC.	Director/Board Member	11/06/2013
Pattern Pharma, Inc. Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical industry	Director/Board Member	-
MycRx MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein	Chief Executive Officer	01/01/2020

All active positions of Nick Glover

Former positions of Nick Glover

Companies	Position	End
SIERRA ONCOLOGY, INC.	Chief Executive Officer	22/05/2020
YM BioSciences, Inc. YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products	Chief Executive Officer	01/02/2013
University Medical Discoveries, Inc. University Medical Discoveries, Inc. Investment ManagersFinance UMDI focuses on seed and early-stage investments in the medical and life sciences. They help develop and commercialize research done by entrepreneurs and scientists at Canadian universities, hospitals and research institutes. The CIHR, MDS, and MedTech Partners Inc have also joined forces to launch the University Medical Discoveries Fund (UMDF). The CMDF is considered a partner of the UMDF. The UMDF’s “focus is to help develop and commercialize early-stage biomedical innovations” at Canadian universities and since 1996 it has invested in 31 early stage companies. This relationship between the CIHR and CMDF goes further.	Private Equity Analyst	31/03/2009
Viventia Biotech, Inc. Viventia Biotech, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and commercializes monoclonal antibody products	Chief Executive Officer	01/06/2008
ProNAi Therapeutics Inc ProNAi Therapeutics Inc BiotechnologyHealth Technology Operates as a biopharmaceutical drug development company that develops nucleic-acid drugs	Chief Executive Officer	-

See the detail of Nick Glover's experience

Education of Nick Glover

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nick Glover's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	12
YM BioSciences, Inc. YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products	Health Technology
Viventia Biotech, Inc. Viventia Biotech, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and commercializes monoclonal antibody products	Health Technology
Sierra Oncology, Inc. Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases	Health Technology
Lumira Capital Investment Management, Inc. Lumira Capital Investment Management, Inc. Investment ManagersFinance LUMIRA invests in revenue stage companies that are both privately held and publically traded companies located in the Canada and the United States. The firm focuses on sectors of therapeutic products and medical devices. It participates in the early stage capital financing.	Finance
MEI Pharma, Inc. MEI Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products	Health Technology
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Simon Fraser University Simon Fraser University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of East Anglia University of East Anglia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University Medical Discoveries, Inc. University Medical Discoveries, Inc. Investment ManagersFinance UMDI focuses on seed and early-stage investments in the medical and life sciences. They help develop and commercialize research done by entrepreneurs and scientists at Canadian universities, hospitals and research institutes. The CIHR, MDS, and MedTech Partners Inc have also joined forces to launch the University Medical Discoveries Fund (UMDF). The CMDF is considered a partner of the UMDF. The UMDF’s “focus is to help develop and commercialize early-stage biomedical innovations” at Canadian universities and since 1996 it has invested in 31 early stage companies. This relationship between the CIHR and CMDF goes further.	Finance
Pattern Pharma, Inc. Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical industry	Health Technology
MycRx MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein	Commercial Services
ProNAi Therapeutics Inc ProNAi Therapeutics Inc BiotechnologyHealth Technology Operates as a biopharmaceutical drug development company that develops nucleic-acid drugs	Health Technology